. These shares were acquired through open market purchases in the fourth quarter of 2021. In the third quarter of 2021, Philips had already entered into a number of forward transactions, covering approximately half of this program, with settlement dates in 2022, 2023 and 2024.

Further details on Philips’ current repurchase program and previous programs can be found here.

* For capital reduction purposes

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.